Skip to main content
COGT
NASDAQ Life Sciences

Director-Affiliated Fund Files Intent to Sell $127.4M in Cogent Biosciences Shares

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$39.53
Mkt Cap
$6.011B
52W Low
$3.72
52W High
$43.73
Market data snapshot near publication time

summarizeSummary

A fund associated with a director of Cogent Biosciences has filed a Form 144 to sell 3.5 million shares, valued at $127.4 million, indicating a significant insider-affiliated disposition.


check_boxKey Events

  • Director-Affiliated Fund Files Intent to Sell

    Fairmount Healthcare Fund II L.P., an entity associated with director Peter Harwin, filed a Form 144 to sell 3,500,000 shares of common stock.

  • Significant Proposed Sale Value

    The proposed sale has an approximate market value of $127.4 million, representing a substantial portion of the company's market capitalization.


auto_awesomeAnalysis

Fairmount Healthcare Fund II L.P., an entity associated with Peter Harwin, a director of Cogent Biosciences, has filed a Form 144 indicating its intent to sell 3,500,000 shares. This proposed sale, valued at approximately $127.4 million, represents a significant portion of the company's market capitalization. Such a large insider-affiliated disposition could signal a lack of confidence or a strategic portfolio adjustment by a key investor, potentially creating downward pressure on the stock.

At the time of this filing, COGT was trading at $39.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $3.72 to $43.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed COGT - Latest Insights

COGT
Apr 23, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
9
COGT
Apr 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
COGT
Mar 31, 2026, 9:30 PM EDT
Filing Type: 144
Importance Score:
9
COGT
Mar 31, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
COGT
Mar 16, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
COGT
Feb 17, 2026, 9:24 AM EST
Filing Type: 10-K
Importance Score:
9
COGT
Feb 17, 2026, 8:12 AM EST
Filing Type: 8-K
Importance Score:
8
COGT
Jan 22, 2026, 8:09 PM EST
Filing Type: 4
Importance Score:
9
COGT
Jan 22, 2026, 8:05 PM EST
Filing Type: 144
Importance Score:
8
COGT
Jan 22, 2026, 8:02 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7